Lionco Pharm Grp Co Ltd
Lionco Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products and medical services in China. It offers chemical and prescription drugs for nutrition, antimicrobial, antiviral, digestive, cardiovascular, cerebrovascular, detoxification, anti-tumor, and other applications. The company was founded in 2003 a… Read more
Lionco Pharm Grp Co Ltd (603669) - Total Liabilities
Latest total liabilities as of September 2025: CN¥465.93 Million CNY
Based on the latest financial reports, Lionco Pharm Grp Co Ltd (603669) has total liabilities worth CN¥465.93 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lionco Pharm Grp Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Lionco Pharm Grp Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lionco Pharm Grp Co Ltd Competitors by Total Liabilities
The table below lists competitors of Lionco Pharm Grp Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
VNV Global AB
ST:VNV
|
Sweden | Skr91.18 Million |
|
Dilip Buildcon Limited
NSE:DBL
|
India | ₹144.99 Billion |
|
Hwashin
KO:010690
|
Korea | ₩957.05 Billion |
|
Shenzhen New Land Co Ltd
SHE:300778
|
China | CN¥188.45 Million |
|
ASRock Rack Incorporation
TW:7711
|
Taiwan | NT$5.23 Billion |
|
Agrana Beteiligungs AG
XETRA:AGB2
|
Germany | €1.35 Billion |
|
United Malacca Bhd
KLSE:2593
|
Malaysia | RM319.41 Million |
|
VRG SA
WAR:VRG
|
Poland | zł644.61 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Lionco Pharm Grp Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lionco Pharm Grp Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lionco Pharm Grp Co Ltd (2011–2024)
The table below shows the annual total liabilities of Lionco Pharm Grp Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥485.57 Million | -29.98% |
| 2023-12-31 | CN¥693.52 Million | -3.72% |
| 2022-12-31 | CN¥720.32 Million | -31.76% |
| 2021-12-31 | CN¥1.06 Billion | -14.62% |
| 2020-12-31 | CN¥1.24 Billion | +106.19% |
| 2019-12-31 | CN¥599.60 Million | -13.10% |
| 2018-12-31 | CN¥689.97 Million | +95.79% |
| 2017-12-31 | CN¥352.40 Million | +101.87% |
| 2016-12-31 | CN¥174.57 Million | -22.06% |
| 2015-12-31 | CN¥223.98 Million | +20.61% |
| 2014-12-31 | CN¥185.70 Million | -19.64% |
| 2013-12-31 | CN¥231.09 Million | +79.61% |
| 2012-12-31 | CN¥128.67 Million | +11.08% |
| 2011-12-31 | CN¥115.83 Million | -- |